Corticosteroid-loaded biodegradable nanoparticles for prevention of corneal allograft rejection in rats
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
Immunologic graft rejection is one of the main causes of short and long-term graft failure in corneal transplantation. Steroids are the most commonly used immunosuppressive agents for postoperative management and prevention of corneal graft rejection. However, steroids delivered in eye drops are rapidly cleared from the surface of the eye, so the required frequency of dosing for corneal graft rejection management can be as high as once every 2 h. Additionally, these eye drops are often prescribed for daily use for 1 year or longer, which can result in poor patient compliance and steroid-related side effects. Here, we report a biodegradable nanoparticle system composed of Generally Regarded as Safe (GRAS) materials that can provide sustained release of corticosteroids to prevent corneal graft rejection following subconjunctival injection provided initially during transplant surgery. Poly(lactic-co-glycolic acid) (PLGA) nanoparticles containing dexamethasone sodium phosphate (DSP) exhibited a size of 200 nm, 8 wt.% drug loading, and sustained drug release over 15 days in vitro under sink conditions. DSP-loaded nanoparticles provided sustained ocular drug levels for at least 7 days after subconjunctival administration in rats, and prevented corneal allograft rejection over the entire 9-week study when administered weekly. In contrast, control treatment groups that received weekly injections of either placebo nanoparticles, saline, or DSP in solution demonstrated corneal graft rejection accompanied by severe corneal edema, neovascularization and opacity that occurred in ≤ 4 weeks. Local controlled release of corticosteroids may reduce the rate of corneal graft rejection, perhaps especially in the days immediately following surgery when risk of rejection is highest and when typical steroid eye drop administration requirements are particularly onerous.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Antiinflammatory Action of Glucocorticoids — New Mechanisms for Old Drugs
Rhen, T., & Cidlowski, J. A. (2005) · New England Journal of Medicine · doi:10.1056/nejmra050541 · Cited by 3,149
Nance, E. A., Woodworth, G. F., Sailor, K. A., Shih, T.-Y., Xu, Q., Swaminathan, G., Xiang, D., Eberhart, C., & Hanes, J. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003594 · Cited by 649
Self-citationMechanisms and resistance in glucocorticoid control of inflammation
Barnes, P. J. (2010) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2010.02.018 · Cited by 317
Di Tommaso, C., Bourges, J.-L., Valamanesh, F., Trubitsyn, G., Torriglia, A., Jeanny, J.-C., Behar-Cohen, F., Gurny, R., & Möller, M. (2012) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2012.02.014 · Cited by 128
Cited by
Therapeutic Nanoparticles and Their Targeted Delivery Applications
Yetisgin, A. A., Cetinel, S., Zuvin, M., Kosar, A., & Kutlu, O. (2020) · Molecules · doi:10.3390/molecules25092193 · Cited by 1,080
Polymeric Nanoparticles for Drug Delivery: Recent Developments and Future Prospects
Begines, B., Ortiz, T., Pérez-Aranda, M., Martínez, G., Merinero, M., Argüelles-Arias, F., & Alcudia, A. (2020) · Nanomaterials · doi:10.3390/nano10071403 · Cited by 1,061
Review of the efficacy of nanoparticle-based drug delivery systems for cancer treatment
Elumalai, K., Srinivasan, S., & Shanmugam, A. (2024) · Biomedical Technology · doi:10.1016/j.bmt.2023.09.001 · Cited by 649
Nanotechnology-based strategies for treatment of ocular disease
Weng, Y., Liu, J., Jin, S., Guo, W., Liang, X., & Hu, Z. (2017) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2016.09.001 · Cited by 375
Han, H., Li, S., Xu, M., Zhong, Y., Fan, W., Xu, J., Zhou, T., Ji, J., Ye, J., & Yao, K. (2023) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2023.114770 · Cited by 322
Effects of engineered nanoparticles on the innate immune system
Liu, Y., Hardie, J., Zhang, X., & Rotello, V. M. (2017) · Seminars in Immunology · doi:10.1016/j.smim.2017.09.011 · Cited by 315
Gaballa, S. A., Kompella, U. B., Elgarhy, O., Alqahtani, A. M., Pierscionek, B., Alany, R. G., & Abdelkader, H. (2021) · Drug Delivery and Translational Research · doi:10.1007/s13346-020-00843-z · Cited by 255
Subconjunctival injectable dendrimer-dexamethasone gel for the treatment of corneal inflammation
Soiberman, U., Kambhampati, S. P., Wu, T., Mishra, M. K., Oh, Y., Sharma, R., Wang, J., Al Towerki, A. E., Yiu, S., Stark, W. J., et al. (2017) · Biomaterials · doi:10.1016/j.biomaterials.2017.02.016 · Cited by 170
“outcomes, such as reduction in neovascularization, preservation of corneal clarity and reduction of inflammation, with subconjunctival depot injections of steroids [17, 18, 2023].”
Self-citationXu, X., Wu, Y., Gu, R., Zhang, Z., Liu, X., Hu, Y., Li, X., Lin, D., & Bao, Z. (2024) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2024.114351 · Cited by 14
Metadata
- Authors
- Pan, Q., Xu, Q., Boylan, N. J., Lamb, N. W., G. Emmert, D., Yang, J.-C., Tang, L., Heflin, T., Alwadani, S., Eberhart, C. G., Stark, W. J., & Hanes, J.
- Venue
- Journal of Controlled Release
- Publisher
- Elsevier BV
- Published
- 2015-03
- Volume
- 201
- Pages
- 32-40
- ISSN
- 0168-3659 (ISSN-L)
- OpenAlex
- W2063707766
- Cited by
- 94
- References
- 4
- FWCI
- 4.37
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.